Asset Details
Do you wish to reserve the book?
Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder
Do you wish to request the book?
Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder
2014
Overview
Summary Aims The purpose of this study was to assess the safety, tolerability and impact on overactive bladder (OAB) symptoms of a novel combination of tolterodine immediate‐release (IR) 2 mg and delayed‐release pilocarpine 9 mg in patients with OAB. Methods Eligible patients with OAB were randomised to each of three treatments [tolterodine/pilocarpine (2/9 mg), tolterodine IR 2 mg or placebo] twice daily for 4 weeks in a double‐blind, crossover fashion. At the end of the 12‐week, double‐blind treatment period, patients could enter an open‐label extension during which they were re‐randomised to either tolterodine/pilocarpine (3/13.5 mg) twice daily or tolterodine extended‐release 4 mg once daily for 12 weeks. Results A total of 138 patients were randomised to double‐blind medication. Both tolterodine/pilocarpine (2/9) and tolterodine IR 2 mg significantly reduced incontinence episodes and daily micturitions (p < 0.001 vs. placebo), with similar reductions in symptoms observed between active treatment groups. Tolterodine/pilocarpine (2/9) was associated with consistently lower Visual Analogue Scale (VAS) scores for all dry mouth parameters compared with tolterodine alone. Salivary flow over a 3 h period remained fairly constant after tolterodine/pilocarpine (2/9) administration, similar to placebo, but decreased markedly after administration of tolterodine alone. In the extension study, patients receiving tolterodine/pilocarpine (3/13.5) reported comparable dry mouth VAS scores to tolterodine extended‐release alone without additional side effects or loss of efficacy. The combination was well tolerated, and the adverse effects observed were consistent with the known safety profiles of tolterodine and pilocarpine. Conclusions A combination of tolterodine/pilocarpine (2/9) effectively reduced the incidence of dry mouth compared with tolterodine IR alone while maintaining treatment efficacy in OAB.
Publisher
Blackwell Publishing Ltd,John Wiley & Sons, Inc
Subject
/ Aged
/ Bladder
/ Female
/ Humans
/ Mouth
/ Muscarinic Antagonists - adverse effects
/ Patients
/ Pilocarpine - administration & dosage
/ Pilocarpine - adverse effects
/ Pilocarpine - therapeutic use
/ Placebos
/ Tolterodine Tartrate - administration & dosage
/ Tolterodine Tartrate - adverse effects
/ Tolterodine Tartrate - therapeutic use
/ Urinary Bladder, Overactive - drug therapy
/ Urology
